These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38723108)

  • 1. Comment on: Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
    Chen IW; Chang LC; Hung KC
    J Antimicrob Chemother; 2024 Jul; 79(7):1717-1718. PubMed ID: 38723108
    [No Abstract]   [Full Text] [Related]  

  • 2. Molnupiravir: A new candidate for COVID-19 treatment.
    Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molnupiravir for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):10-11. PubMed ID: 35134041
    [No Abstract]   [Full Text] [Related]  

  • 4. Molnupiravir for the Treatment of Coronavirus Disease 2019: A Systematic Review With Meta-Analysis of 12,451 Patients.
    Beran A; Mhanna A; Mhanna M; Farrow D; Sidiki S; Khader Y; Srour O; Kayyali A
    Am J Ther; 2024 Jan-Feb 01; 31(1):e47-e50. PubMed ID: 38231582
    [No Abstract]   [Full Text] [Related]  

  • 5. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.
    Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R
    J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis.
    Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M
    APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
    Eloy P; Le Grand R; Malvy D; Guedj J
    EBioMedicine; 2021 Dec; 74():103663. PubMed ID: 34768087
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis.
    Amani B; Amani B
    Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RdRp inhibitors and COVID-19: Is molnupiravir a good option?
    Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H
    Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of COVID-19 in high-risk outpatients.
    Med Lett Drugs Ther; 2022 Feb; 64(1643):e1. PubMed ID: 35134051
    [No Abstract]   [Full Text] [Related]  

  • 14. Molnupiravir versus favipiravir in at-risk outpatients with COVID-19: A randomized controlled trial in Thailand.
    Salvadori N; Jourdain G; Krittayaphong R; Siripongboonsitti T; Kongsaengdao S; Atipornwanich K; Sakulkonkij P; Angkasekwinai N; Sirijatuphat R; Chusri S; Mekavuthikul T; Apisarnthanarak A; Srichatrapimuk S; Sungkanuparph S; Kirdlarp S; Phongnarudech T; Sangsawang S; Napinkul P; Achalapong J; Khusuwan S; Pratipanawat P; Nookeu P; Danpipat N; Leethong P; Hanvoravongchai P; Sukrakanchana PO; Auewarakul P
    Int J Infect Dis; 2024 Jun; 143():107021. PubMed ID: 38561040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molnupiravir: First Approval.
    Syed YY
    Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molnupiravir reduces symptoms duration but does not decrease hospitalizations or deaths in vaccinated adults with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):400-401. PubMed ID: 39269353
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molnupiravir or nirmatrelvir-ritonavir reduce the likelihood of hospitalization and mortality in immunocompromised patients with Covid-19.].
    Kurotschka PK; Ebell MH; Serafini A
    Recenti Prog Med; 2024 Sep; 115(9):399. PubMed ID: 39269352
    [No Abstract]   [Full Text] [Related]  

  • 18. Covid-19: Results from India's 12 molnupiravir clinical trials remain unpublished.
    Mahase E
    BMJ; 2022 Aug; 378():o2063. PubMed ID: 35985657
    [No Abstract]   [Full Text] [Related]  

  • 19. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
    Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
    Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial.
    Alpizar SA; Accini J; Anderson DC; Eysa B; Medina-Piñón I; Ohmagari N; Ostrovskyy MM; Aggrey-Amable A; Beck K; Byrne D; Grayson S; Hwang PMT; Lonchar JD; Strizki J; Xu Y; Paschke A; De Anda CS; Sears PS;
    J Infect; 2023 Nov; 87(5):392-402. PubMed ID: 37690669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.